- Trials with a EudraCT protocol (7)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
7 result(s) found for: Common iliac vein.
Displaying page 1 of 1.
EudraCT Number: 2005-004486-42 | Sponsor Protocol Number: CaVenT | Start Date*: 2006-01-03 |
Sponsor Name:Eastern Norway Regional Health Authority [...] | ||
Full Title: Catheter-directed Venous Thrombolysis (CaVenT) in Acute Iliofemoral Vein Thrombosis - an open Randomized, Controlled, Clinical Trial | ||
Medical condition: Acute ilio-femoral vein thrombosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-001723-12 | Sponsor Protocol Number: ARIVA_venous | Start Date*: 2020-05-28 |
Sponsor Name:Universitätsspital Zürich, Klinik für Angiologie | ||
Full Title: Aspirin® plus rivaroxaban versus rivaroxaban alone for the prevention of venous stent thrombosis in patients with post-thrombotic syndrome | ||
Medical condition: Post-thrombotic syndrome | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) DE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2005-002536-94 | Sponsor Protocol Number: 1160.47 | Start Date*: 2006-03-20 |
Sponsor Name:Boehringer Ingelheim Finland Ky | ||
Full Title: A phase III, randomised, multicenter, double-blind, parallel-group, active controlled study to evaluate the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2... | ||
Medical condition: Confirmed Venous Thromboembolism (VTE) i.e. uni or bilateral deep vein thrombosis (DVT) of the leg involving proximal veins and/or pulmonay embolism (PE) - treated with anticoagulant for 3 to 6 mo... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FI (Completed) AT (Completed) SE (Completed) CZ (Completed) BE (Completed) SK (Completed) GB (Completed) ES (Completed) DE (Completed) HU (Completed) PT (Completed) GR (Completed) DK (Completed) IT (Completed) BG (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-006014-41 | Sponsor Protocol Number: Vasovist MA-01 | Start Date*: 2008-04-14 | |||||||||||
Sponsor Name:University Heidelberg, University Hospital Mannheim | |||||||||||||
Full Title: Determination of Diagnostic Accuracy and Added Value of Vasovist®-Enhanced Peripheral MRA in Comparison to Intra-arterial Digital Subtraction Angiography (i.a. DSA) in Patients with Peripheral Arte... | |||||||||||||
Medical condition: Patients suffering from PAOD stage III or stage IV (confirmed by ECCM MRA, CTA, non-selective DSA, DUS) and have an indication for the evaluation of the entire lower leg axis down to the feet (comm... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-018141-20 | Sponsor Protocol Number: IN0901INT | Start Date*: 2010-06-30 | |||||||||||
Sponsor Name:LEO Pharma A/S | |||||||||||||
Full Title: Eficacia y Seguridad del Tratamiento a Largo Plazo (6 meses) con Innohep® frente a Anticoagulación con un Antagonista de la Vitamina K (Warfarina) para el Tratamiento del Tromboembolismo Venoso Agu... | |||||||||||||
Medical condition: Tromboembolismo venoso (TEV) en pacientes con cáncer activo. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) DE (Completed) SK (Completed) CZ (Completed) AT (Completed) PT (Completed) IT (Completed) DK (Completed) GR (Completed) LV (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-001999-12 | Sponsor Protocol Number: 1160.53 | Start Date*: 2006-03-14 |
Sponsor Name:Boehringer Ingelheim Ltd. | ||
Full Title: A phase III, randomised, double blind, parallel-group study of the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0-3.0) for 6 month treatment of acute sy... | ||
Medical condition: Acute symptomatic venous thromboembolism (VTE), i.e. uni- or bilateral deep vein thrombosis (DVT) of the leg involving proximal veins, and/or pulmonary embolism (PE) confirmed by definitive objecti... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) FI (Completed) SE (Completed) DK (Completed) AT (Completed) BE (Completed) ES (Completed) HU (Completed) CZ (Completed) PT (Completed) GR (Completed) IT (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-002631-86 | Sponsor Protocol Number: 1160.46 | Start Date*: 2008-10-23 | ||||||||||||||||
Sponsor Name:Boehringer Ingelheim Austia Gm.b.H | ||||||||||||||||||
Full Title: A phase III, randomised, double blind, parallel-group study of the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0-3.0) for 6 month treatment of acute sy... | ||||||||||||||||||
Medical condition: Acute symptomatic VTE VTE is defined as the composite incidence of Deep Vein Thrombosis of the leg (including the inferior caval vein) and Pulmonary Embolism. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BG (Completed) SK (Completed) ES (Completed) GB (Completed) NL (Completed) DK (Completed) CZ (Completed) SE (Completed) HU (Completed) FR (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
